HOME >> MEDICINE >> NEWS
Duke Study Uses Tiny Temperature Changes To Probe Water-Exclusion At Protein Binding Sites

SAN FRANCISCO -- In research that could lead to better drug design, a Duke University bioorganic chemist is exploiting the differences between two forms of water to probe how proteins' shapes control the way they bind with other molecules.

Such binding reactions, which occur constantly in watery solutions within our bodies, require removing much of the water in and around the protein's binding site to make room for the binding partner, said Eric Toone, a Duke associate professor of chemistry.

Removing this water provides much of the energy that drives a binding reaction, and determining how much energy this removal provides has previously been impossible, he added in an interview.

Toone, who made his deductions using a supersensitive instrument that can measure 1 millionths of a degree temperature changes, prepared his findings for presentation at the American Chemical Society's national meeting.

Toone's research is supported by the National Institutes of Health, the Camille Dreyfus Foundation and the Alfred P. Sloan Foundation.

Molecular binding events control many biological processes within our bodies, from the activity of enzymes to the signaling that takes place within cells. And blocking these binding events using synthetic molecules is the basis of action of almost all pharmaceutical compounds, Toone said.

Chemical reactions in the body typically unfold when smaller molecules, called "ligands" form temporary combinations, called complexes, with protein molecules at special protein binding sites. Pharmaceutical researchers can elicit biological effects by designing drugs to link up with proteins just as natural ligands do. But in the process the drugs block the natural action of the protein.

Toone said a "holy grail" of pharmaceutical chemistry -- the so-called "rational design"of drugs -- requires that scientists know enough about the architecture of proteins to devise
'"/>

Contact: Monte Basgall
basgallm@mail01.adm.duke.edu
919-681-8057
Duke University
14-Apr-1997


Page: 1 2 3 4

Related medicine news :

1. Study of energy and health in Africa focuses spotlight on charcoal and forest management
2. Study shows promise in identifying kidney failure
3. Study shows patch therapy may be as effective as oral medications
4. Study shows soy is well accepted in school lunches
5. Study finds that coordinating care of chronically ill patients does not increase liability
6. Study provides new estimates of the causes of child mortality worldwide
7. Study finds factors linked to substance use disorder relapse among health care professionals
8. Study finds majority of women willing to accept cervical cancer vaccine for self and children
9. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
10. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
11. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women

Post Your Comments:
(Date:6/18/2013)... (PRWEB) June 19, 2013 Looking for a ... monotony of everyday life? , IWALKAWAKE is a guide ... Written by Adam Botha, it focuses on harnessing the powerful ... The book lays out a nine-step guide to finding one’s ... that a person must go through to reach their true ...
(Date:6/18/2013)... Daily Gossip Magazine has always kept its readers entertained ... , The magazine has decided to prepare readers for the ... recipe every week . , According to Daily Gossip ... readers who are looking to get insights into this type ... anabolic food is almost entirely based on healthy, yet tasteful ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 SEATTLE, WA—A ... Farms of Fairview, Oregon, claiming he fell ill with ... berry and pomegranate seed blend. The complaint was ... by Marler Clark, the Seattle-based law firm that has ... , According to the complaint, Brian Brothers consumed “Townsend ...
(Date:6/18/2013)... Warner, NH (PRWEB) June 18, 2013 ... rugged, submersible, battery powered, stand-alone device which can be ... The new stainless steel enclosure of the Temp1000IS comes ... device interfaces with the IFC400 (sold separately) ... docking station for full communications. No more removal of ...
(Date:6/18/2013)... Senior drug regulatory officials from mainland China and Taiwan ... first time in the U.S.—the need for more collaboration between ... in a timely manner. Representatives from the Taiwan and mainland ... and processes in drug review during the Convergence in ... DIA 2013 49th Annual Meeting . , While ...
Breaking Medicine News(10 mins):Health News:Anabolic Cooking Book Review Exposes Dave Ruel’s Top 10 ‘Anabolicious’ Recipes for BodyBuilders 2Health News:Marler Clark, Washington Resident Sue Townsend Farms Over Hepatitis A 2Health News:Marler Clark, Washington Resident Sue Townsend Farms Over Hepatitis A 3Health News:MadgeTech, Inc. Introduces the New Temp1000IS Intrinsically Safe High Temperature Data Logger 2Health News:Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting 2
(Date:6/18/2013)... , Safinamide significantly improves ... as add-on to levodopa Safinamide is ... in fluctuating PD patients as add-on to levodopa ... ("Newron"), a research and development company focused on ... Zambon S.p.A., a pharmaceutical company strongly committed to ...
(Date:6/18/2013)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... VPII Escrow Corp., a newly formed wholly owned Canadian ... approximately $3.2 billion aggregate principal amount of senior unsecured ... 2021 and in 2023, with final tranching determined at ... net proceeds from the offering, together with proceeds from ...
(Date:6/18/2013)... 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ICPT ... development and commercialization of novel bile acid therapeutics to ... an underwritten public offering of 1,730,000 shares of its ... per share.  In addition, Intercept has granted the underwriters ... 259,500 shares of common stock. All of ...
Breaking Medicine Technology:Safinamide Phase III Study Results Presented at 2013 MDS Meeting 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 3Safinamide Phase III Study Results Presented at 2013 MDS Meeting 4Safinamide Phase III Study Results Presented at 2013 MDS Meeting 5Safinamide Phase III Study Results Presented at 2013 MDS Meeting 6Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
Cached News: